Ingantattun Tasirin Antitumor na 4-1BB-Tsashen CD19 CAR-T Kwayoyin a Magance B-ALL

A cikin wani muhimmin bincike na asibiti da asibitin Lu Daopei da Cibiyar Lu Daopei na Hematology suka gudanar, masu bincike sun gano cewa 4-1BB na tushen CD19 CAR-T Kwayoyin suna ba da kyakkyawan zaɓi ga ƙwayoyin CAR-T na CD28 na al'ada don magance sake dawowa ko raguwa. B cell m lymphoblastic cutar sankarar bargo (r/r B-ALL). Wannan binciken, wanda ya haɗa da tsauraran bincike na asibiti da bincike na asibiti, ya nuna cewa 4-1BB CAR-T Kwayoyin ba kawai suna samar da ingantaccen maganin ƙwayar cuta ba amma suna nuna tsayin daka a cikin marasa lafiya idan aka kwatanta da takwarorinsu na CD28.

Tawagar masu bincike na asibitin Lu Daopei sun kwatanta aikin waɗannan nau'ikan tantanin halitta guda biyu na CAR-T. Sun gano cewa, a ƙarƙashin tsarin masana'antu iri ɗaya, sel 4-1BB CAR-T suna da tasirin antitumor mafi ƙarfi a ƙananan allurai kuma sun haifar da ƙarancin mummunan al'amura fiye da sel CD28 CAR-T. Sakamakon binciken ya nuna cewa 4-1BB na tushen CAR-T na iya ba da zaɓin magani mafi inganci da aminci ga marasa lafiya da ke fama da r / r B-ALL.

Wadannan binciken sun nuna jajircewar da asibitin Lu Daopei ya yi na inganta ilimin jini da na rigakafi, yana ba da bege ga marasa lafiya da ba su amsa maganin al'ada ba. Binciken, wanda ya bi ka'idoji masu tsauri kuma ya sami amincewa daga Kwamitin Da'a na Asibitin Lu Daopei, ya jaddada rawar da asibitin ke takawa wajen jagorantar bincike mai zurfi a cikin hanyoyin kwantar da hankali na CAR-T.

Tare da wannan ci gaba, Cibiyar Lu Daopei na Hematology ta ci gaba da yin gyare-gyaren sababbin iyakokin bincike na likitanci, tare da samar da zaɓuɓɓukan jiyya da kuma inganta sakamakon haƙuri. Wannan ci gaban shaida ce ga sadaukarwa da ƙwararrun ƙungiyoyin likitoci da na asibitin Lu Daopei.